Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
A number of other equities research analysts have also weighed in on the stock. BTIG Research set a $21.00 price objective on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a report on Monday, December 18th. Piper Jaffray Companies lowered their price target on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, October 31st. Zacks Investment Research lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Robert W. Baird reiterated a “buy” rating and set a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Finally, ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.75.
Shares of Oxford Immunotec Global (OXFD) opened at $12.13 on Friday. The firm has a market cap of $306.83, a P/E ratio of -6.00 and a beta of -0.30. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.51.
In related news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $12.01, for a total transaction of $36,030.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.11% of the company’s stock.
A number of large investors have recently bought and sold shares of OXFD. Consonance Capital Management LP bought a new stake in Oxford Immunotec Global during the 4th quarter valued at $15,645,000. Perceptive Advisors LLC raised its holdings in Oxford Immunotec Global by 955.1% during the 3rd quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock valued at $7,818,000 after buying an additional 421,250 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in Oxford Immunotec Global by 44.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after buying an additional 413,904 shares during the last quarter. Redmile Group LLC raised its holdings in Oxford Immunotec Global by 13.0% during the 4th quarter. Redmile Group LLC now owns 2,318,387 shares of the company’s stock valued at $32,388,000 after buying an additional 266,900 shares during the last quarter. Finally, RTW Investments LP raised its holdings in Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after purchasing an additional 185,453 shares in the last quarter. Institutional investors own 88.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/02/25/oxford-immunotec-global-oxfd-upgraded-to-hold-at-bidaskclub.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.